NEORIN SYRUP 150ML

Indications

Approved Uses

Symptomatic relief of seasonal and perennial allergic rhinitis (nasal and non-nasal symptoms) and chronic idiopathic urticaria (pruritus and reduction of hives).

Dosage & Administration

Dosing by Condition

Allergic rhinitis and chronic idiopathic urticaria: Adults/adolescents ≥12 years: 5 mg once daily (10 mL of 0.5 mg/mL). Children 6-11 years: 2.5 mg once daily (5 mL). Children 1-5 years: 1.25 mg once daily (2.5 mL). Children 6-11 months: 1 mg once daily (2 mL).

Initial Dose

Adults and adolescents ≥12 years: 5 mg (10 ml) once daily

Maintenance Dose

5 mg (10 ml) once daily for adults; weight/age-based dosing for children

Maximum Dose

5 mg per day (adults and adolescents ≥12 years)

Children's Dosage

6-11 months: 1 mg (2 ml) once daily; 1-5 years: 1.25 mg (2.5 ml) once daily; 6-11 years: 2.5 mg (5 ml) once daily; ≥12 years: 5 mg (10 ml) once daily

How to Take

Oral use; may be taken once daily with or without food; shake the bottle well before each dose; measure using an accurate oral syringe/cup (not a household spoon).

Side Effects

Common Side Effects

Headache, dry mouth, fatigue, pharyngitis, nausea, myalgia, somnolence (rare at therapeutic doses)

Safety & Warnings

Contraindications

Hypersensitivity to desloratadine, loratadine, or any of its ingredients.

Age Restriction

Approved from 6 months of age (for perennial allergic rhinitis and chronic idiopathic urticaria); seasonal allergic rhinitis is typically from 2 years and older.

Driving Warning

Does not cause drowsiness

Drug Interactions

Drug Interactions

Ketoconazole, erythromycin, azithromycin, fluoxetine, and cimetidine may increase desloratadine exposure; clinically significant effects are uncommon.

Interaction Severity

Clinically significant interactions are uncommon; moderate/monitoring interactions include strong CYP/P-gp inhibitors such as ketoconazole and erythromycin (may increase desloratadine exposure). Other listed agents (e.g., azithromycin, fluoxetine, cimetidine) generally have minimal clinical impact but can be considered monitoring-level depending on patient factors.

Food Interaction

No restriction.

Special Populations

Pregnancy

Consult Doctor

Breastfeeding

Consult Doctor

Children

6-11 months: 1 mg (2 ml) once daily; 1-5 years: 1.25 mg (2.5 ml) once daily; 6-11 years: 2.5 mg (5 ml) once daily; ≥12 years: 5 mg (10 ml) once daily

Liver Impairment

Hepatic impairment: start 5 mg every other day in adults (and age-appropriate reduced-frequency dosing in children); use caution especially in severe impairment.

Storage & Patient Advice

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next dose, skip the missed dose and resume the regular schedule; do not double the dose.

Stopping the Medicine

Safe to stop anytime.

Overdose

Overdose is usually not life-threatening but may cause somnolence, tachycardia, and headache; manage with symptomatic/supportive care, consider decontamination if recent, and note hemodialysis does not remove desloratadine-seek medical/poison-center advice.

Patient Counseling

Take once daily with or without food; shake well and measure doses accurately; may cause drowsiness in some-use caution with driving until effects are known and avoid alcohol if drowsy; do not exceed recommended dose; store below 30°C (per SFDA); seek medical advice if symptoms persist/worsen or if you have kidney/liver disease.

Monitoring Requirements

No routine monitoring.

Pharmacology

Mechanism of Action

Selective peripheral histamine H1-receptor antagonist; desloratadine (active metabolite of loratadine) competitively blocks H1 receptors to reduce allergic symptoms with minimal CNS effects at usual doses.

Onset of Action

Within 1 hour.

Duration of Effect

24 hours.

Half-Life

Approximately 27 hours.

Metabolism

Extensively metabolized (primarily hepatic) to the active metabolite 3‑hydroxydesloratadine, followed by glucuronidation; the specific CYP enzymes responsible have not been definitively identified (not reliably CYP3A4/CYP2C8).

Excretion

Eliminated via both urine and feces (approximately similar proportions; e.g., ~41% urine and ~47% feces reported).

Protein Binding

Desloratadine: 82-87% protein bound; 3‑hydroxydesloratadine: 85-89% protein bound.

Product Information

Available Dosage Forms

Syrup/oral solution, film-coated tablet, orally disintegrating tablet (ODT).

Composition per Dose

Each 5 ml: desloratadine 2.5 mg (0.5 mg/ml)

Generic Availability

Yes

OTC Alternatives

Other OTC second-generation antihistamines: loratadine, cetirizine, levocetirizine, fexofenadine (including age-appropriate liquid formulations where needed).

Symptom Target

Allergy, Runny Nose

Sedating

No

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 11-07-2026